146 related articles for article (PubMed ID: 37920752)
1. Association Between
Yuan H; Wang C; Liu L; Wang C; Zhang Z; Qu S
Pharmgenomics Pers Med; 2023; 16():925-932. PubMed ID: 37920752
[TBL] [Abstract][Full Text] [Related]
2. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
[TBL] [Abstract][Full Text] [Related]
3. Association between SOST gene polymorphisms and response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.
Wang WJ; Fu WZ; He JW; Wang C; Zhang ZL
Pharmacogenomics J; 2019 Oct; 19(5):490-498. PubMed ID: 30287911
[TBL] [Abstract][Full Text] [Related]
4.
Zhao J; Liu L; Lv S; Wang C; Yue H; Zhang Z
Pharmgenomics Pers Med; 2021; 14():1669-1678. PubMed ID: 34992429
[TBL] [Abstract][Full Text] [Related]
5. Associations of Serum Cathepsin K and Polymorphisms in
Gao LH; Li SS; Yue H; Zhang ZL
Front Endocrinol (Lausanne); 2020; 11():48. PubMed ID: 32117071
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
7. Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Liu Y; Liu H; Li M; Zhou P; Xing X; Xia W; Zhang Z; Liao E; Chen D; Liu J; Tao T; Wu W; Xu L
Chin Med J (Engl); 2014; 127(4):662-8. PubMed ID: 24534219
[TBL] [Abstract][Full Text] [Related]
8. Association between NF-
Shen X; Tan S; Feng X; Fu W; Hu Y; Li M; Wang W; Yuan H; Liu L; Wang C; Hua F
Evid Based Complement Alternat Med; 2022; 2022():2461716. PubMed ID: 35368772
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
Medicine (Baltimore); 2018 Aug; 97(31):e11694. PubMed ID: 30075569
[TBL] [Abstract][Full Text] [Related]
10. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
11. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
12. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
13. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller PD; Epstein S; Sedarati F; Reginster JY
Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
[TBL] [Abstract][Full Text] [Related]
16. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
17. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
18. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.
Bell NH; Bilezikian JP; Bone HG; Kaur A; Maragoto A; Santora AC;
J Clin Endocrinol Metab; 2002 Jun; 87(6):2792-7. PubMed ID: 12050252
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
